MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen

Acta Oncologica

Volumn 53, Issue 6, 2014, Pages 769-775

  Tengström, Maria ^a,b,c   Mannermaa, Arto ^a,c,d   Kosma, Veli Matti ^a,c,d   Soini, Ylermi ^a,c,d   Hirvonen, Ari ^e   Kataja, Vesa ^a,b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Biocenter Kuopio   (Finland)

^e FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; TAMOXIFEN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERCC2 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; BREAST NEOPLASMS; CARCINOMA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; DISEASE SEVERITY; DNA DAMAGE; GENE; MNSOD GENE; MONOTHERAPY; PREDICTION; WILD TYPE; XPD GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE; TAMOXIFEN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84900499984     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.892210     Document Type: Article

References (27)

1. Robertson D W , Katzenellenbogen JA , Long DJ , Rorke EA , Katzenellenbogen BS . Tamoxifen antiestrogens . A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 1982 ; 16 : 1-13 .
2. Gelmann EP . Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma . Semin Oncol 1997 ; 24(1 Suppl 1) : S1 - 65 - S1 - 70 .
3. Spitz DR , Azzam EI, Li JJ, Gius D . Metabolic oxidation/ reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology . Cancer Metastasis Rev 2004 ; 23 : 311-22 .
4. Kovacic P , Osuna JA , Jr . Mechanisms of anti-cancer agents: Emphasis on oxidative stress and electron transfer . Curr Pharm Des 2000 ; 6 : 277-309 .
5. Klaunig JE, Kamendulis LM , Hocevar BA . Oxidative stress and oxidative damage in carcinogenesis . Toxicol Pathol 2010 ; 38 : 96-109 .
6. Ozben T . Oxidative stress and apoptosis: Impact on cancer therapy . J Pharm Sci 2007 ; 96 : 2181-96 .
7. Ferlini C, Scambia G , Marone M , Distefano M , Gaggini C, Ferrandina G , et al . Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines . Br J Cancer 1999 ; 79 : 257-63 .
8. Kallio A , Zheng A , Dahllund J , Heiskanen KM , Harkonen P . Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells . Apoptosis 2005 ; 10 : 1395-410 .
9. Pfanner N , Geissler A . Versatility of the mitochondrial protein import machinery . Nat Rev Mol Cell Biol 2001 ; 2 : 339-49 .
10. Sutton A , Khoury H , Prip-Buus C , Cepanec C , Pessayre D , Degoul F . The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria . Pharmacogenetics 2003 ; 13 : 145-57 .
11. Park SY , Chang I , Kim JY , Kang SW , Park SH , Singh K, et al . Resistance of mitochondrial DNA-depleted cells against cell death: Role of mitochondrial superoxide dismutase . J Biol Chem 2004 ; 279 : 7512-20 .
12. Ambrosone C B, Ahn J , Singh KK, Rezaishiraz H , Furberg H , Sweeney C , et al . Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer . Cancer Res 2005 ; 65 : 1105-11 .
13. Bewick MA , C onlon MS , Lafrenie RM . Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer . Breast Cancer Res Treat 2008 ; 111 : 93-101 .
14. Glynn SA , Boersma BJ, Howe TM , Edvardsen H, Geisler SB , Goodman JE , et al . A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide . Clin Cancer Res 2009 ; 15 : 4165-73 .
15. Yao S , Barlow WE, Albain KS , Choi JY , Zhao H, Livingston RB , et al . Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer . Breast Cancer Res Treat 2010 ; 124 : 433-9 .
16. Hou SM , Falt S , Angelini S , Yang K, Nyberg F , Lambert B , et al . The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk . Carcinogenesis 2002 ; 23 : 599-603 .
17. Chew HK, Doroshow JH, Frankel P , Margolin KA , Somlo G , Lenz HJ , et al . Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer . J Clin Oncol 2009 ; 27 : 2163-9 .
18. Pabalan N , Francisco-Pabalan O , Sung L , Jarjanazi H , Ozcelik H . Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer . Breast Cancer Res Treat 2010 ; 124 : 531-41 .
19. Bewick MA , Lafrenie RM , Conlon MS . Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer . J Cancer Res Clin Oncol 2011 ; 137 : 543-50 .
20. Hartikainen J M , Kataja V , Pirskanen M , Arffman A , Ristonmaa U , Vahteristo P , et al . Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families . Clin Genet 2007 ; 72 : 311-20 .
21. Mitrunen K , Sillanpaa P , Kataja V , Eskelinen M , Kosma VM , Benhamou S , et al . Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk . Carcinogenesis 2001 ; 22 : 827-9 .
22. Razandi M , Pedram A , Jordan VC , Fuqua S , Levin ER . Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer . Oncogene 2013 ; 32 : 3274-85 .
23. Cho S K , Pedram A , Levin E R , Kwon Y J . Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD) . Biomaterials 2013 ; 34 : 10228-37 .
24. Wozniak K , Kolacinska A , Blasinska-Morawiec M , Morawiec-Bajda A , Morawiec Z , Zadrozny M , et al . The DNA-damaging potential of tamoxifen in breast cancer and normal cells . Arch Toxicol 2007 ; 81 : 519-27 .
25. Ray G , Husain SA . Oxidants, antioxidants and carcinogenesis . Indian J Exp Biol 2002 ; 40 : 1213-32 .
26. Mandlekar S , Yu R , Tan TH , Kong AN . Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells . Cancer Res 2000 ; 60 : 5995-6000 .
27. MacCallum J, Cummings J, Dixon JM , Miller WR . Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours . Br J Cancer 2000 ; 82 : 1629-35 .